Morphine does not facilitate breast cancer progression in two preclinical mouse models for human invasive lobular and HER2⁺ breast cancer

Morphine and other opioid analgesics are potent pain-relieving agents routinely used for pain management in patients with cancer. However, these drugs have recently been associated with a worse relapse-free survival in patients with surgical cancer, thus suggesting that morphine adversely affects ca...

Full description

Saved in:
Bibliographic Details
Published in:Pain (Amsterdam) Vol. 156; no. 8; pp. 1424 - 1432
Main Authors: Doornebal, Chris W, Vrijland, Kim, Hau, Cheei-Sing, Coffelt, Seth B, Ciampricotti, Metamia, Jonkers, Jos, de Visser, Karin E, Hollmann, Markus W
Format: Journal Article
Language:English
Published: United States 01.08.2015
Subjects:
Analgesics, Opioid - administration & dosage
Analgesics, Opioid - adverse effects
Animals
Breast Neoplasms - complications
Breast Neoplasms - pathology
Breast Neoplasms - psychology
Carcinoma, Lobular - pathology
Disease Models, Animal
Disease Progression
Female
Genes, erbB-2 - genetics
Humans
Mammary Glands, Animal - drug effects
Mammary Glands, Animal - pathology
Mice
Mice, Knockout
Morphine - administration & dosage
Morphine - adverse effects
Neoplasm Invasiveness - pathology
Pain - drug therapy
Pain - etiology
Pain - psychology
Treatment Outcome
ISSN:1872-6623
Online Access:Get more information
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Morphine and other opioid analgesics are potent pain-relieving agents routinely used for pain management in patients with cancer. However, these drugs have recently been associated with a worse relapse-free survival in patients with surgical cancer, thus suggesting that morphine adversely affects cancer progression and relapse. In this study, we evaluated the impact of morphine on breast cancer progression, metastatic dissemination, and outgrowth of minimal residual disease. Using preclinical mouse models for metastatic invasive lobular and HER2 breast cancer, we show that analgesic doses of morphine do not affect mammary tumor growth, angiogenesis, and the composition of tumor-infiltrating immune cells. Our studies further demonstrate that morphine, administered in the presence or absence of surgery-induced tissue damage, neither facilitates de novo metastatic dissemination nor promotes outgrowth of minimal residual disease after surgery. Together, these findings indicate that opioid analgesics can be used safely for perioperative pain management in patients with cancer and emphasize that current standards of "good clinical practice" should be maintained.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1872-6623
DOI:10.1097/j.pain.0000000000000136